{"id":33398,"date":"2020-08-12T18:41:17","date_gmt":"2020-08-12T17:41:17","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33398"},"modified":"2023-05-01T22:14:46","modified_gmt":"2023-05-01T21:14:46","slug":"christophe-le-tourneau","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2019-speakers\/christophe-le-tourneau\/","title":{"rendered":"Christophe Le Tourneau"},"content":{"rendered":"
\n\n\t

Christophe Le Tourneau<\/h2>\n

Senior Medical Oncologist & Professor of Medicine at Institut Curie & Versailles-Saint-Quentin-en-Yvelines University<\/h4>\n\t

Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at the Versailles-Saint-Quentin-en-Yvelines University. He is heading the Department of Drug Development and Innovation as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007.<\/p>\n

He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology.<\/p>\n

He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advances cancer. He has published 120+ peer-reviewed papers in international journals.<\/p>\n\t\t\t\t\t\t\t\"Christophe_Le_Tourneau_Marie_Curie_BioTech_Pharma_Summit_2\"\t\t\t\t\t\t\t\n

\n\tTitle: Should every cancer patient be sequenced?\n\t<\/h3>\n